Publications

• Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study

  J. C. Becker, J. C. Hassel, C. Menzer, K. C. Kähler, T. K. Eigentler, F. E. Meier, C. Berking, R. Gutzmer, P. Mohr, F. Kiecker, M. Kaatz, C. Windemuth-Kieselbach, C. Lorenz-Schlüter, L. Zimmer, S.Ugurel, Dirk Schadendorf, and German Dermatooncology Group (DeCOG/ADO)

  PMID: Show Details link to full text
  Study

  ADMEC-O

  Year

  2018

  Keywords

  • Merkel cell carcinoma
  • skin cancer
  • ipilimumab
  • oncology

• Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]

  F. Griesinger, S. Radke, A. Lüers, B. Deschler-Baier, M. Kimmich, M. Sebastian, C. Schulz, W. Brugger, R. Wiewrodt, R. Pirker, M. Früh, O. Gautschi, J. Wolf

  PMID: 30408830 Show Details link to full text
  Study

  Pneumologie 30408830

  Year

  2018

  Keywords

  • lung cancer
  • EGFR-TKI resistance
  • Osimertnip
  • oncology

• Dermatologic Cooperative Oncology Group (DeCOG). Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.

  U. Hillen, U. Leiter, S. Haase, R. Kaufmann, J. Becker, R. Gutzmer, P. Terheyden, A. Krause-Bergmann, H. J. Schulze, J. Hassel, N. Lahner, U. Wollina, F. Ziller, J. Utikal, C. Hafner, J. Ulrich, H. G. Machens, C. Weishaupt, A. Hauschild, P. Mohr, C. Pföhler, J. Maurer, P. Wolff, C. Windemuth-Kieselbach, D. Schadendorf, E. Livingstone

  PMID: 29665511 Show Details link to full text
  Study

  Year

  2018

  Keywords

  • squamous cell carcinoma
  • oncology
  • skin cancer

• Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study

  R. D. Hofheinz, C. Lange, T. Ecke, S. Kloss, B. Linsse, C. Windemuth-Kieselbach, P. Hammerer, S. E. Al-Batran

  PMID: 27618249 Show Details link to full text
  Study

  QoLiTime

  Year

  2017

  Keywords

  • cabazitaxel
  • mCRPC
  • QoL
  • oncology

• The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial

  B. A. S. Jaeger BAS, J. Neugebauer, U. Andergassen, C. Melcher, F. Schochter, D. Mouarrawy, G. Ziemendorff, M. Clemens, V. E. Abel, G. Heinrich, K. Schueller, A. Schneeweiss, P. Fasching, M. W. Beckmann, C. Scholz, T. W. P. Friedl, K. Friese, K. Pantel, T. Fehm, W. Janni, B. Rack

  PMID: 28586395 Show Details link to full text
  Study

  SUCCESS B

  Year

  2017

  Keywords

  • HER2
  • breast cancer
  • oncology

• Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.

  T.Biester, B. Aschemeier, M. Fath, M. Frey, M. F. Scheerer, O. Kordonouri, T. Danne

  PMID: 28417527 Show Details link to full text
  Study

  DAPA IIT179

  Year

  2017

  Keywords

  • dapagliflozin
  • type 1 diabetes

• PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives

  J. Sehouli, E. I. Braicu, R. Chekerov

  PMID: 26941449 Show Details link to full text
  Study

  Year

  2016

  Keywords

  • PARP inhibitors
  • ovarian cancer
  • oncology

• The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).

  S. E. Al-Batran, W. Hozaeel, F. K. Tauchert, R. D. Hofheinz, A. Hinke, C. Windemuth-Kieselbach, A. Hübner, M. Burmester, M. Koenigsmann, J. Wiegand, G. Zur Hause, B. Linsse, R. Kuhl, C. Pauligk

  PMID: 25755108 Show Details link to full text
  Study

  QoliTax

  Year

  2015

  Keywords

  • docetaxel
  • metastatic colorectal cancer
  • QoL
  • oncology
  • HRQoL

• Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study

  R. Chekerov, G. Kaltenecker, D. Reichert, T. Göhler, P. Klare, G. Oskay-Özcelik, U. Sauer, A. Wischnik, U. Vehling-Kaiser, M. Becker, U. Hutzschenreuter, A. Ammon, E. Heidrich-Lorsbach, J. Sehouli

  PMID: 26637909 Show Details link to full text
  Study

  Year

  2015

  Keywords

  • Treosulfan
  • ovarian cancer
  • oncology

• Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial

  S. Kasper, J. Meiler, H. Knipp, T. Höhler, P. Reimer, T. Steinmetz, W. Berger, G. Linden, H. Reis, P. Markus, A. Paul, A. Dechêne, B. Schumacher, K. Kostbade, I. Virchow, S. Ting, K. Worm, K. W. Schmid, T. Herold, M. Wiesweg, M. Schuler, T.Trarbach

  PMID: 26637909 Show Details link to full text
  Study

  CEBIFOX

  Year

  2015

  Keywords

  • BRAF mutation
  • metastatic colorectal cancer
  • RAS mutation
  • cetuximab
  • oncology